CNEN

Welcome to Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.!

Search

Copyright:  Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.!   京ICP备19006400号-1​     Powered by 300.cn

美科

Links:

Stem cell drugs formulated with Stemedica’s products approved in Kazakhstan for treatment of acute myocardial infarction

Source:
Release time:
2018/09/12 15:34
Page view

With a license granted by CardioCell LLC (a shareholding company of Stemedica) to treat cardiovascular indications with it-hMSCs, ALTACO XXI from Kazakhstan successfully completed a Phase III clinical trial in Kazakhstan and submitted an application for listing the product as a new drug to Kazak authorities. On September 12, 2018, the Ministry of Kazakhstan approved the application of Stemedica manufactured stem cells as a therapy to acute myocardial infarction, officially bringing it-hMSCs into clinical settings.

 

Stem cell drugs formulated with Stemedica’s products approved in Kazakhstan for treatment of acute myocardial infarctionStem cell drugs formulated with Stemedica’s products approved in Kazakhstan for treatment of acute myocardial infarction